Insider Selling: Retrophin Inc (RTRX) SVP Sells 1,250 Shares of Stock
Retrophin Inc (NASDAQ:RTRX) SVP William E. Rote sold 1,250 shares of the company’s stock in a transaction on Friday, February 15th. The stock was sold at an average price of $21.44, for a total transaction of $26,800.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
William E. Rote also recently made the following trade(s):
- On Tuesday, February 19th, William E. Rote sold 2,500 shares of Retrophin stock. The stock was sold at an average price of $21.48, for a total transaction of $53,700.00.
RTRX stock traded down $0.16 during trading on Wednesday, hitting $20.95. 239,700 shares of the company’s stock traded hands, compared to its average volume of 337,524. Retrophin Inc has a 52 week low of $19.77 and a 52 week high of $33.00. The company has a quick ratio of 4.99, a current ratio of 5.04 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $889.30 million, a P/E ratio of -13.97 and a beta of 1.38.
RTRX has been the subject of a number of research reports. Jefferies Financial Group initiated coverage on shares of Retrophin in a research report on Tuesday, October 30th. They set a “buy” rating and a $44.00 target price for the company. Nomura initiated coverage on shares of Retrophin in a research report on Monday, November 19th. They set a “buy” rating and a $57.00 price objective for the company. ValuEngine lowered shares of Retrophin from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 17th. BidaskClub lowered shares of Retrophin from a “buy” rating to a “hold” rating in a research report on Friday, January 11th. Finally, Zacks Investment Research lowered shares of Retrophin from a “hold” rating to a “strong sell” rating in a research report on Thursday, November 8th. Two analysts have rated the stock with a sell rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $48.00.
Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.